Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999361 | 0.84 | HTR2A (0.42) | PKMLMNASLC6A4 | |
| SCHEMBL5505035 | 0.82 | HTR6 (0.44) | SOS1LMNAHTR6 | |
| SCHEMBL6000147 | 0.81 | HTR2A (0.43) | PRKCISOS1ADRB2LMNAKDR | |
| SCHEMBL5998731 | 0.78 | PTGS1 (0.48) | SOS1KDRMAPTHTR6 | |
| SCHEMBL5503713 | 0.77 | SOS1 (0.49) | SOS1SLC6A4 | |
| SCHEMBL5503825 | 0.76 | BRD4 (0.45) | SOS1LMNAHTR6SLC6A4 | |
| SCHEMBL6000529 | 0.75 | HTR2A (0.46) | PRKCISOS1ADRB2KDRSLC6A4 | |
| SCHEMBL18184512 | 0.75 | PKM (0.55) | PRKCIPKMLMNAPKLR | |
| SCHEMBL27873084 | 0.68 | ADRB2 (0.58) | ADRB2HTR6 | |
| SCHEMBL5497370 | 0.68 | SOS1 (0.41) | SOS1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | PRKCI 3695/4885SOS1 3837/4885PKM 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.